FDA grants authorization to 23andMe for direct-to-consumer genetic test for cancer risk

(c) 23andMe

23andMe, Inc. has received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows the company to provide customers, without a prescription, information on three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer.